2Macleod MJ, Mclay J. Drug treatment of hypertension complicating diabetes mellitus [ J ]. Drugs, 1998, 56(2): 189-202.
3Tamasawa N, Matsui J, Ogawa Y, et al. Effect of doxazosin on the size of LDL particle in the type 2 diabetic patients with hypertension [ J ]. Diabetes Complications, 2000,14(3) :135-139.
4Totsuka M, Miyashita Y, Ito Y, et al. The effect of celiprolol hydrochloride for lipid metabolism-especially for the low density lipoprotein particle size [ J ].Nippon Ronen Igakkai Zasshi, 2001,38(3) :352-359.
5Noguchi N, Nishino K, Niki E. Antioxidant action of the antihypertensive drug, carvedilol, against lipid peroxidation[ J ]. Biochem Pharmacol, 2000, 59(9) :1069-1076.
6Pressel S, Davis BR, Louis G T, et al. Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ( ALLHAT) [J]. Control Clin Trials, 2001,22(6): 674-686.
7Ahaneku JE, Sakata K, Urano T, et al. Influence of baseline values on lipids,lipeproteins and fibrinolytic parameters during amlodipine treatment of hypertension in Japanese patients [ J ]. Pharmacol Res, 2001,41 ( 1 ): 75-79.
8Ashida T. Treatment of hypertension with dyslipidemia [ J ]. Nippon Rinsho,2001,59 (5) :978-982.
9Sanz M, Ganado P, Tejerina T. Two angiotensin AT1 receptor antagonists, irbesartan and losartan, effects in cholesterol-fed rabbits [ J ]. Eur J Pharmacol, 2002, 3:99-106.
10Nielsen S, Hove KY, Dollerup J, et al. Losartan modifies glomerular hyperfiltration and insulin sensitivity in type 1 diabetes [ J ]. Diabetes Obes Metab,2001,3(6) :463-467.
